Tuberculous meningitis: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
Line 74: | Line 74: | ||
| +4 |
| +4 |
||
|} |
|} |
||
=== Complications and Prognosis === |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
**Mental retardation, psychiatric disorders, seizures, blindness, deafness, ophthalmoplegia, hemiparesis |
|||
==Differential Diagnosis== |
==Differential Diagnosis== |
||
Line 104: | Line 113: | ||
*Standard HREZ x2mo then HR x7-10mo |
*Standard HREZ x2mo then HR x7-10mo |
||
**Can replace ethambutol with a fluoroquinolone |
**Can replace ethambutol with a fluoroquinolone |
||
*Adjunctive steroids for high risk of IRIS |
|||
*Dexamethasone 3mg po qid x2wk then taper over 6-8wks |
**[[Dexamethasone]] 3mg po qid x2wk then taper over 6-8wks |
||
**High risk of IRIS |
|||
**Prednisolone 120 mg PO daily x1wk, 90 mg x1wk, 60 mg x1wk, 30 mg x1wk, 15 mg x1wk, 5 mg x1wk |
|||
{| class="wikitable" |
{| class="wikitable" |
||
Line 197: | Line 207: | ||
|No data |
|No data |
||
|} |
|} |
||
==Prognosis== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
**Mental retardation |
|||
**Psychiatric disorders |
|||
**Seizures |
|||
**Blindness |
|||
**Deafness |
|||
**Ophthalmoplegia |
|||
**Hemiparesis |
|||
==Further Reading== |
==Further Reading== |
Revision as of 15:29, 7 April 2022
- Meningeal infection by Mycobacterium tuberculosis
- High mortality, often needs empiric treatment even before confirmed diagnosis
Background
Classification
- Stage 1: normal level of consciousness, no focal neurological deficits
- Stage 2: decreased level of consciousness, significant focal neurological deficits
- Stage 3: seizures, comatose
Epidemiology
- About 1% of TB cases in Canada
Risk Factors
- Young
- Female
- Originally from endemic country
- Previous TB
Clinical Manifestations
History
- Prodrome (1-3 weeks)
- Personality changes
- Low-grade fever
- Malaise
- Weight loss
- Gradual onset of worsening headache
- Headache
- Fevers
- Vomiting
- Confusion
- Personality changes
- Photophobia (only 5-10%)
- Seizures
Physical Exam
- Meningeal symptoms
- Fevers
- Vomiting
- Meningismus
- Focal neurological deficits
- Cranial nerve palsies in VI, III, and IV
- Hemiplegia, paraplegia
- Urinary retention
- Confusion, coma
Thwaites Index
- Used to differentiate bacterial from tuberculous meningitis in adults before results of CSF culture are available1
- Tuberculous more likely if score ≤4; bacterial more likely if score ≥5
- Sensitivity 86% and specificity 79%
Item | Score |
---|---|
Age ≥36 years | +2 |
Blood WBC ≥15 | +4 |
≥6 days of illness | -5 |
CSF WBC ≥900x103 | +3 |
CSF % PMN ≥75 | +4 |
Complications and Prognosis
- Depends on stage at presentation
- Mortality is high
- Stage 1: 10-20%
- Stage 2: 20-40%
- Stage 3: 60%
- Morbidity is high, with about 20% of patient being left with significant neurological sequelae
- Mental retardation, psychiatric disorders, seizures, blindness, deafness, ophthalmoplegia, hemiparesis
Differential Diagnosis
- Fungal meningitis
- Sarcoidosis
- Neoplasm
- Other causes of chronic meningitis
Investigations
- Lumbar puncture
- Increased lymphocytes, decreased glucose, and increased protein
- Need 3-5mL of CSF for culture
- May need serial LPs
- CT head
Diagnosis
- Gold standard is mycobacterial culture (71% sensitive, 100% specific)
- Sensitivity increases with volume and number of samples
- Microscopy for acid-fast bacilli is 20-80% sensitive and 100% specific
- PCR is 85-95% sensitive and 98% specific
- Used to confirm but not exclude the diagnosis
Management
- Rule out neoplasm and fungus, then start empiric treatment
- HIV test (delay antiretrovirals by 8 weeks, though)
- Standard HREZ x2mo then HR x7-10mo
- Can replace ethambutol with a fluoroquinolone
- Adjunctive steroids for high risk of IRIS
- Dexamethasone 3mg po qid x2wk then taper over 6-8wks
- Prednisolone 120 mg PO daily x1wk, 90 mg x1wk, 60 mg x1wk, 30 mg x1wk, 15 mg x1wk, 5 mg x1wk
Drug | Dose | Duration | CSF penetration |
---|---|---|---|
Rifampin | 10 mg/kg (max 600 mg) | 12 months | 10-20% |
Isoniazid | 5 mg/kg (max 300 mg) | 12 months | 80-90% |
Pyrazinamide | 25 mg/kg | 2 months | 90-100% |
Ethambutol | 15 mg/kg | 2 months | 20-30% |
Second-line treatments | |||
Levofloxacin | 10-15 mg/kg | Throughout treatment | 70-80% |
Moxifloxacin | 400 mg | Throughout treatment | 70-80% |
Amikacin | 15 mg/kg (max 1 g) | Intensive phase only | 10-20% |
Kanamycin | 15 mg/kg (max 1 g) | Intensive phase only | 10-20% |
Capreomycin | 15 mg/kg (max 1 g) | Intensive phase only | Probably very low |
Ethionamide or prothionamide | 15-20 mg/kg (max 1 g) | Throughout treatment | 80-90% |
Cycloserine | 10-15 mg/kg (max 1 g) | Throughout treatment | 80-90% |
Linezolid | 600 mg | Throughout treatment | 30-70% |
Other drugs with uncertain benefit | |||
Clofazimine | 100 mg daily | Probably low | |
p-aminosalicylic acid | 200-300 mg/kg | Probably very low | |
Bedaquiline | Probably very low | ||
Delamanid | No data |
Further Reading
- Treatment of Tuberculous Meningitis and Its Complications in Adults. Curr Treat Options Neurol. 2018;20(3):5. doi: 10.1007/s11940-018-0490-9
References
- ^ GE Thwaites, TTH Chau, K Stepniewska, NH Phu, LV Chuong, DX Sinh, NJ White, CM Parry, JJ Farrar. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. The Lancet. 2002;360(9342):1287-1292. doi:10.1016/s0140-6736(02)11318-3.